A Multicenter, Randomized, Double Blind, Placebo (PB) Controlled Trial of Marimastat (MT) In Patients with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS) Following Completion of Conventional, First-Line Treatment

Heather Jones, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 13 de mayo del 2001

Translation for this article does not exist